MRC-Gard
Feasibility Study on Estimating the Prevalence and Management of Stage 4 Chronic Kidney Disease in Adults Via Laboratories and Nephrologists in the Gard, France
Sponsor study identifier
observational
3,375
1 country
4
Study Start
January 1, 2019
Actual (reported)Primary Completion
December 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
December 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
The main objective of this study is to evaluate the feasibility of estimating the prevalence of stage 4 and 5 chronic kidney disease in the Gard department of France from data obtained via laboratory databases. To verifiy if the demand for care thus authenticated by laboratory tests is adapted to nephrology care delivery, as recommended by the French High Authority of Health (HAS), laboratory data will be compared with those of patients seen by nephrologists in the department.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
October 18, 2016
Actual (reported)October 19, 2016
Actual (reported)January 1, 2019
Actual (reported)December 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
December 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
The prevalence of chronic kidney disease stage > = 4 in the Gard according to laboratory data (raw number)
from baseline (day 0) to 12 months
The prevalence of chronic kidney disease stage > = 4 in the Gard according to laboratory data (%)
from baseline (day 0) to 12 months
The percentage of patients with CKD stage >= 4 correctly reported by participating nephrologists
from baseline (day 0) to 12 months
For each nephrologist participating in the study, the % of patients with stage >=4 chronic kidney disease who are correctly declared
from baseline (day 0) to 12 months
The % of patients with chronic kidney disease stage > = 4 in the Gard according to laboratory data and who are not seen by a nephrologist
from baseline (day 0) to 12 months
Persons with stage \>=4 chronic kidney disease.
Persons with \>= stage 4 chronic kidney disease and residing in the Gard department of France.
Contact the study team to confirm eligibility.
AIDER - Unité de Dialyse d'Alès
Alès, 30100, France
AIDER - Unité de Dialyse de Nîmes, CHU Carémeau
Nîmes, 30029, France
Olivier Moranne, MD, PhD
Centre Hospitalier Universitaire de Nīmes
First Submitted
October 18, 2016
First Posted
October 19, 2016
Study Start
January 1, 2019
Actual (reported)Primary Completion
December 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Creation and Validation of a Questionnaire to Measure the Feelings of a Chronic Renal Insufficiency Person During His Hemodialysis
CHU de Nîmes - Hôpital Universitaire Carémeau
Nîmes, 30029, France
Gardialyse
Nîmes, 30900, France
Study Completion
December 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
October 20, 2026
Record last verified: 2026-10
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: